<DOC>
	<DOCNO>NCT01774370</DOCNO>
	<brief_summary>This prospective , non-interventional , open-label , multi-centre study . It provide additional safety information Pradaxa Korean patient non-valvular AF clinical setting .</brief_summary>
	<brief_title>SPARK : Safety Study Pradaxa Atrial Fibrillation Patients Regulatory Requirement Korea</brief_title>
	<detailed_description>Study Design : regulatory PMS study</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Age &gt; = 18 year enrollment Patients start Pradaxa accordance approve label Korea Patients sign data release consent form Exclusion criterion : Patients previous exposure Pradaxa Clinically significant bleeding Increased risk bleed due follow disease ; Recent gastrointestinal ulceration Recent intracranial intracerebral bleed history Intraspinal intracerebral vascular abnormality Recent brain , spinal ophthalmic surgery Recent brain spinal injury Known suspect oesophageal varix Arteriovenous malformation Vascular aneurysms Presence malignant neoplasms high risk bleed Concomitant treatment anticoagulant e.g . unfractionated heparin ( UFH ) , low molecular weight heparin ( enoxaparin , dalteparin etc ) , heparin derivative ( fondaparinux etc ) , oral anticoagulant ( warfarin , rivaroxaban , apixaban etc ) except circumstance switch therapy Pradaxa UFH give dos necessary maintain open central venous arterial catheter Severe renal impairment ( CrCl &lt; 30mL/min ) Concomitant treatment oral ketoconazole dronedarone Patients hypersensitive dabigatran dabigatran etexilate ingredient formulation Prosthetic heart valve replacement No creatinine clearance collect within least one year prior enrollment Current participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>